TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00089908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1delta30
Description: Live attenuated rDEN1delta30 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1delta30
Description: Live attenuated rDEN1delta30 vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rDEN1delta30
Study: NCT02562742

Intervention type: DRUG
Intervention: SOF
Description: SOF 400 mg tablets administered orally once daily

Intervention type: DRUG
Intervention: REB
Description: REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
Study: NCT01793155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training, as a supplement to placebo comparator, starts the day before surgery and continues for two weeks after surgery. No sessions are performed on the surgery day. Each session consists of 2 sets of 30 inspirations with a pause between each set of 2 minutes. The target intensity before surgery is 30% of the measured MIP and starts at 15% after surgery. The intensity is incrementally increased by 2 cm H20 the first days after surgery. Patients grade their perceived exertion and register eventual adverse effects in a training diary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo comparator: standard physiotherapy
Description: Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: standard physiotherapy
Description: Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
Study: NCT00706134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken once daily in the morning with a light meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Description: Aliskiren 75 mg tablet taken once daily in the morning with a light meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Description: Aliskiren 150 mg tablet taken once daily in the morning with a light meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Description: Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
Study: NCT01339559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor.
Study: NCT02670642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study: NCT04195321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: infusion will be started after induction of spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine
Description: infusion will be started after induction of spinal anesthesia
Study: NCT01137773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional insulin treatment
Description: All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
Study: NCT02325219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 50 mg
Description: Participants will receive subcutaneous injection of CNTO 1959 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 50 mg
Description: Participants will receive subcutaneous injection of CNTO 1959 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTNO 1959 100 mg
Description: Participants will receive subcutaneous injection of CNTO 1959 100 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTNO 1959 100 mg
Description: Participants will receive subcutaneous injection of CNTO 1959 100 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 50 mg
Description: Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 50 mg
Description: Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100 mg
Description: Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100 mg
Description: Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
Study: NCT01657409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A (10 injection)
Description: BoNT-A 100 U 10 injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A (20 injection)
Description: BoNT-A 100 U 20 injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A (40 injection)
Description: BoNT-A 100 U 40 injections
Study: NCT03747601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporal Interference (TI) Stimulation
Description: 2-4 Temporal Interference stimulation sessions. The device is an experimental non-invasive electrical brain stimulator that functions similar to existing non-significant risk devices for electrical stimulation, including human non-invasive brain stimulation. Briefly, the device produces alternating current electrical stimulation in a kilohertz (kHz) range and results in less net charge applied within the brain. The device is powered by rechargeable 20 volt (V) battery (i.e. there is no connection to building power supply). The current is hardwired and limited to 5 milliamp (mA) via internal resistors. It includes extra safety features such as onboard fuses to limit any abrupt high current, and an emergency stop button which effectively insulates the subject and resets the device. The device was tested and characterized at all the required load conditions.
Study: NCT01088074

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Histoacryl Tissue Adhesive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staples

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl 4-0
Study: NCT02436707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT00817531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: pill form, 100 mg daily
Study: NCT02239939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vest
Description: light weight, adjustable, vest to be worn underneath clothes that weight can be added to

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
Study: NCT01210339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole/ASA
Description: 20 mg/81 mg once daily for five days (Day 5-9)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole/ASA
Description: 20 mg/81 mg once daily for five days (Day 5-9)
Study: NCT01870401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix DCB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncoated PTA Catheter
Study: NCT04273178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalating prophylaxis
Description: For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
Study: NCT01916265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Study: NCT03470493

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ApneaLink Air
Description: ApneaLink Air to be used on each participant undergoing PSG
Study: NCT03066427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg/d
Study: NCT00716105

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant formula
Description: From 3 to 12 months of age. As per standard requirement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula with different level of proteins
Description: From 3 to 12 months of age. As per standard requirement
Study: NCT00452699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Description: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250 mcg BID
Description: Fluticasone propionate 250 mcg BID
Study: NCT02105454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir (GZR)
Description: 100 mg oral tablet (total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir (EBR)
Description: 10 mg oral capsule (total daily dose = 5 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200 mg oral capsule (total daily dose = 4-7 capsules)
Study: NCT00648375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Description: Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take a single dose of placebo immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive therapy workbook
Description: Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapy workbook
Description: Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
Study: NCT03189446

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal Cuff Brachytherapy
Description: Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV on day 1 of a 21 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
Study: NCT04395794

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2-test
Description: Nasopharyngeal and oropharyngeal testing for SARS-CoV-2

Intervention type: OTHER
Intervention: SARS-CoV-2 questionnaire survey
Description: Questionnaire regarding SARS-CoV-2 symptoms and contact with COVID patients
Study: NCT00609479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Description: 1. Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.~2. Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Description: 1. Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.~2. Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12.
Study: NCT01707472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: 700 mg intravenously for a total of 12 infusions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: 700 mg intravenously for a total of 12 infusions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: 700 mg intravenously for a total of 12 infusions.
Study: NCT02217605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
Study: NCT02095535

Intervention type: DRUG
Intervention: Chlorhexidine gluconate
Description: antiseptic
Study: NCT01412593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
Study: NCT00623480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Treated according to the Kogenate FS package insert indications and study physician recommendations
Study: NCT00568646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
Study: NCT02665507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GaAlAs 808nm laser
Description: Hand held superpulsed GaAlAs 808 nm LLLI

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Hand held laser that emits no LLLI
Study: NCT01259609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars Plana Vitrectomy
Description: 25-gauge three-port pars plana vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy
Description: 25-gauge three-port pars plana vitrectomy
Study: NCT01330238

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid vs. placebo
Description: Single infusion of zoledronic acid or placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid vs. placebo
Description: Single infusion of zoledronic acid or placebo
Study: NCT03801668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound Paclitaxel plus S-1
Description: Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin plus S-1
Description: Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
Study: NCT02916355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl
Description: subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl
Description: subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Study: NCT00004262

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spectroscopy
Description: Undergo plasma-atomic emission spectroscopy (DCP-AES)
Study: NCT05080465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous BM MSC
Description: A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
Study: NCT02750033

Intervention type: DEVICE
Intervention: Multimodal Spectroscopy (MMS)
Description: surgical margin assessment with multimodal optical spectroscopy (MMS) device

Intervention type: DEVICE
Intervention: Multimodal Spectroscopy (MMS)
Description: surgical margin assessment with multimodal optical spectroscopy (MMS) device
Study: NCT02965495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD302 2ml
Description: YYD302 2ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD302 3ml
Description: YYD302 3ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 3ml
Description: phosphate buffered saline 3ml
Study: NCT03124823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow DCI Sensor
Description: Noninvasive pulse oximeter sensor
Study: NCT03776175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 Monotherapy
Description: Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 Monotherapy
Description: Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 Monotherapy
Description: Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 Monotherapy
Description: Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 and PF-06865571 Combination
Description: Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of PF-06865571 (3 tablets of 100 mg each), each to be taken twice daily for 41 days and once on Day 42.
Study: NCT00875745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib-Vorinostat
Description: Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).